Large AI Models in Drug Development: How AI Reshapes the Pharmaceutical R&D Workflow

1. Industry Shift: Why Large Models Are Targeting Drug Development

For several years, programming and code generation have been among the core commercialization scenarios for large AI models. As this area gradually matures, leading AI vendors are looking for the next application market where model capabilities can be fully utilized and sustainable commercial value can be formed. Drug R&D is one direction that has been repeatedly validated.

The pharmaceutical industry has two structural pain points. First, R&D cycles are long and capital-intensive: bringing a new drug from target discovery to market often takes more than ten years and requires huge investment. Second, failure rates are high: many candidate drugs fail at the clinical stage. Traditional R&D relies heavily on expert experience and repeated trial-and-error. It involves many steps and complex collaboration. These characteristics complement what large models are good at: language understanding, code generation, structured reasoning, and knowledge integration. Because drug R&D is highly complex, knowledge-intensive, and coordinated across multiple stages, it has become a natural testbed for deploying large models.

2. A Signal Case: How a Very Small Team Can Move R&D Forward

A notable signal is the emergence of “very small teams”: a biotech company with only one full-time employee used large models to advance a candidate therapy for a rare muscular dystrophy from concept to mouse experiments in less than a year and a half. It also coordinated parallel collaboration with more than ten external laboratories. Its R&D capability was ultimately incorporated into a larger platform’s drug development project.

The value of this case is not its scale, but its paradigm. R&D work that once required large teams and long-term accumulation can now use intelligent tools to significantly improve the output efficiency of individuals and small teams. It also substantially lowers the organizational cost of coordinating external resources and advancing multiple workstreams in parallel. This helps explain why large-model vendors are willing to enter the pharmaceutical space directly: they see the efficiency opportunity created when the R&D workflow is restructured.

3. Full-Process View: How Large Models Fit into Drug Development

From public industry practice, the value of large models is not limited to a single stage. Instead, it spans multiple phases of drug R&D.

3.1 Molecular Design and Structural Optimization

In cell therapy, models have been used to optimize CAR-T-related gene design. One practice showed that relevant genetic instruction fragments can be shortened by about 70%, while cell-surface receptor expression can increase by about one order of magnitude.

In antibody development, models can generate tens of thousands of antibody candidate designs within about one month. Some teams have designed and tested thousands of molecular variants within several weeks. In some cases, binding affinity between optimized antibodies and targets improved by several times.

The essence of this type of work is to let models rapidly screen and iterate within a large candidate space, compressing the “design-evaluate-redesign” loop from weeks to days.

3.2 Experiment Design and Workflow Orchestration

Large models can convert research goals described in natural language into executable experiment plans. They can assist in designing controls, arranging experimental sequences, and interpreting output data.

For projects that require cross-laboratory collaboration, models can also act as an “orchestration layer”: unifying task descriptions, tracking progress across nodes, and aggregating distributed results. This reduces coordination overhead.

3.3 Drug Manufacturing and Compliance Documentation

Drug manufacturing involves many structured and semi-structured documents. Models can automatically review thousands of pages of drug manufacturing documentation. In one practice, a model identified all issues found through manual review and additionally flagged several potential risk points. Review time was reduced from more than twenty hours to less than three hours.

Tasks such as “document understanding + rule comparison + risk annotation” are relatively mature deployment areas for large models and have clear return on investment.

3.4 Clinical Trial Planning

In clinical development, models can analyze early trial protocols and help evaluate the strengths and weaknesses of different trial pathways, patient enrollment strategies, and endpoint designs. This helps R&D teams reduce trial-and-error costs before formal investment.

4. A Realistic View: Where the Capability Boundary Lies

It is important to note that many of the above results come from industry collaborative research and cannot be directly equated with “AI has improved the clinical success rate of drugs.” Improvements in molecular binding capability or receptor expression are still far from final drug efficacy. Between in vitro indicators and clinical effectiveness, there are multiple variables such as pharmacokinetics, safety, and dose window.

A more prudent judgment is therefore: the practical value of large models at the current stage lies in accelerating R&D and reducing cost, not replacing biological validation or clinical trials. They shift the main challenge of R&D from “single-point breakthroughs” to “full-process efficiency.” Understanding this helps avoid overestimating AI-driven pharmaceutical development.

5. Engineering Recommendations for Deployment

To practically deploy large models in drug R&D, the following engineering approach can be considered:

• Data and knowledge governance: Drug R&D involves massive heterogeneous data, including papers, patents, experimental records, and manufacturing documents. It is recommended to manage raw data through object storage, and combine vector-based retrieval with retrieval-augmented generation (RAG) to build a traceable knowledge base. This helps prevent models from generating key conclusions without support.
• Compute and model selection: Molecular design and protein structure prediction require substantial compute. Elastic compute can be used to scale resources on demand. For tasks such as document understanding and solution generation, it is better to choose models with appropriate parameter sizes to balance cost and effectiveness.
• Human-machine collaboration and auditability: Key decisions must be reviewed by domain experts. All model outputs should be logged to support traceability and compliance review. Logging services and monitoring alerts should be integrated to detect abnormal outputs and workflow interruptions promptly.
• Security and compliance: Drug R&D is strictly regulated. Data privacy, intellectual property, and compliance review are present throughout the process. Systems should meet requirements for audit, access control, and data isolation from the beginning of design.

On top of these common capabilities, cloud providers such as Baidu AI Cloud can provide foundational capabilities including large-model platforms, object storage, elastic compute, logging, and monitoring. This helps R&D teams focus on algorithmic logic and biological problems rather than building and maintaining underlying infrastructure.

6. Outlook: From Tools to Infrastructure

The entry of large models into the pharmaceutical industry marks an evolution in which AI is moving from an “auxiliary tool” to “R&D infrastructure.” In the short term, large models are likely to land first in areas with quantifiable efficiency gains, such as document processing, molecule screening, and solution generation. In the medium to long term, as high-quality data accumulates and model capabilities continue to improve, end-to-end acceleration of the R&D workflow becomes possible.

For technical teams, the key is not to chase a single model or tool, but to build a complete engineering system in which “data, models, compute, and compliance” work together. This is both the current practical path for large-model enablement in pharmaceutical R&D and a reusable general paradigm for other high-barrier R&D scenarios, such as materials, energy, and biology. Whoever proves this system first is more likely to gain an advantage in the next round of R&D efficiency competition.